{"id":"https://openalex.org/W2989583243","doi":"https://doi.org/10.1111/bcp.14187","title":"First\u2010in\u2010human, randomized dose\u2010escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF\u201006480605 in healthy subjects","display_name":"First\u2010in\u2010human, randomized dose\u2010escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF\u201006480605 in healthy subjects","publication_year":2019,"publication_date":"2019-11-23","ids":{"openalex":"https://openalex.org/W2989583243","doi":"https://doi.org/10.1111/bcp.14187","mag":"2989583243","pmid":"https://pubmed.ncbi.nlm.nih.gov/31758576","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7098865"},"language":"en","primary_location":{"id":"doi:10.1111/bcp.14187","doi":"https://doi.org/10.1111/bcp.14187","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.14187","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.14187","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.14187","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073909248","display_name":"Christopher R. Banfield","orcid":"https://orcid.org/0000-0002-6321-5792","observed_orcids":["https://orcid.org/0000-0002-6321-5792"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Christopher Banfield","raw_affiliation_strings":["Pfizer Inc, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070826588","display_name":"Dan Rudin","orcid":"https://orcid.org/0000-0002-2298-2012","observed_orcids":["https://orcid.org/0000-0002-2298-2012"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dan Rudin","raw_affiliation_strings":["Pfizer Inc, New Haven, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, New Haven, Connecticut","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032554640","display_name":"Indranil Bhattacharya","orcid":"https://orcid.org/0000-0002-2832-7916","observed_orcids":["https://orcid.org/0000-0002-2832-7916"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Indranil Bhattacharya","raw_affiliation_strings":["Pfizer Inc, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071883134","display_name":"Kosalaram Goteti","orcid":"https://orcid.org/0000-0002-8971-8283","observed_orcids":["https://orcid.org/0000-0002-8971-8283"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kosalaram Goteti","raw_affiliation_strings":["Pfizer Inc, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Gang Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gang Li","raw_affiliation_strings":["Pfizer Inc, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066719024","display_name":"Mina Hassan\u2010Zahraee","orcid":"https://orcid.org/0000-0003-1951-8304","observed_orcids":["https://orcid.org/0000-0003-1951-8304"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mina Hassan\u2010Zahraee","raw_affiliation_strings":["Pfizer Inc, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103238706","display_name":"Lisa S. Brown","orcid":"https://orcid.org/0000-0001-7840-568X","observed_orcids":["https://orcid.org/0000-0001-7840-568X"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa S. Brown","raw_affiliation_strings":["Pfizer Inc, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086384035","display_name":"Kenneth E. Hung","orcid":"https://orcid.org/0000-0002-3911-182X","observed_orcids":["https://orcid.org/0000-0002-3911-182X"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth E. Hung","raw_affiliation_strings":["Pfizer Inc, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109445324","display_name":"Sylvester Pawlak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sylvester Pawlak","raw_affiliation_strings":["Pfizer Inc, New Haven, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, New Haven, Connecticut","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110234816","display_name":"Christopher S. Lepsy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher Lepsy","raw_affiliation_strings":["Pfizer Inc, Andover, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Andover, Massachusetts","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5073909248"],"corresponding_institution_ids":["https://openalex.org/I180857899"],"apc_list":{"value":4000,"currency":"USD","value_usd":4000},"apc_paid":null,"fwci":2.1849,"has_fulltext":true,"cited_by_count":34,"citation_normalized_percentile":{"value":0.88313668,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"86","issue":"4","first_page":"812","last_page":"824"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9380000233650208,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9380000233650208,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.05090000107884407,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0026000000070780516,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tl1a","display_name":"TL1A","score":0.9369999766349792},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.7929999828338623},{"id":"https://openalex.org/keywords/inflammatory-bowel-disease","display_name":"inflammatory bowel disease","score":0.9309999942779541},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7319999933242798},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9340000152587891},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.9309999942779541},{"id":"https://openalex.org/keywords/anti-drug-antibodies","display_name":"anti-drug antibodies","score":0.9729999899864197},{"id":"https://openalex.org/keywords/neutralizing-antibodies","display_name":"neutralizing antibodies","score":0.9789999723434448},{"id":"https://openalex.org/keywords/target-engagement","display_name":"target engagement","score":0.8040000200271606},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7549999952316284},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.7129999995231628},{"id":"https://openalex.org/keywords/intravenous-administration","display_name":"intravenous administration","score":0.8389999866485596},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7680000066757202},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.5920000076293945}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8739466071128845},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8570800423622131},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7953046560287476},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7275277972221375},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.7272018194198608},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.655404269695282},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6517804861068726},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5206698179244995},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3694950342178345},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3637040853500366},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.28768694400787354},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.273257851600647},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.11506235599517822},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057134","descriptor_name":"Antibodies, Neutralizing","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D061605","descriptor_name":"Administration, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1111/bcp.14187","doi":"https://doi.org/10.1111/bcp.14187","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.14187","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.14187","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7098865","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7098865","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"},{"id":"pmid:31758576","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31758576","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1111/bcp.14187","doi":"https://doi.org/10.1111/bcp.14187","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.14187","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.14187","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2989583243.pdf","grobid_xml":"https://content.openalex.org/works/W2989583243.grobid-xml"},"referenced_works_count":42,"referenced_works":["https://openalex.org/W1838836312","https://openalex.org/W1940516511","https://openalex.org/W1974156051","https://openalex.org/W1978824927","https://openalex.org/W1981650730","https://openalex.org/W1986063290","https://openalex.org/W1986852088","https://openalex.org/W1992752307","https://openalex.org/W1995943031","https://openalex.org/W2012041771","https://openalex.org/W2014643802","https://openalex.org/W2014700549","https://openalex.org/W2018857157","https://openalex.org/W2021847144","https://openalex.org/W2046486403","https://openalex.org/W2064955293","https://openalex.org/W2067933166","https://openalex.org/W2070869625","https://openalex.org/W2072907428","https://openalex.org/W2085865745","https://openalex.org/W2087221993","https://openalex.org/W2092113548","https://openalex.org/W2095161324","https://openalex.org/W2102997999","https://openalex.org/W2104160273","https://openalex.org/W2108975227","https://openalex.org/W2118088660","https://openalex.org/W2120389810","https://openalex.org/W2126807394","https://openalex.org/W2137167164","https://openalex.org/W2161890468","https://openalex.org/W2324116490","https://openalex.org/W2329080061","https://openalex.org/W2539630895","https://openalex.org/W2556960393","https://openalex.org/W2557320445","https://openalex.org/W2744702511","https://openalex.org/W2744879509","https://openalex.org/W2746541731","https://openalex.org/W2784524664","https://openalex.org/W2790597722","https://openalex.org/W2885847499"],"related_works":["https://openalex.org/W4408343240","https://openalex.org/W3167136803","https://openalex.org/W7163393600","https://openalex.org/W7125159643","https://openalex.org/W2998778361","https://openalex.org/W3116870415","https://openalex.org/W2317247348","https://openalex.org/W7127366390","https://openalex.org/W7125245738","https://openalex.org/W4411419035"],"abstract_inverted_index":{"AIMS:":[0],"Human":[1],"genetic,":[2],"tissue":[3],"expression,":[4],"proteomics,":[5],"transcriptomics":[6],"and":[7,48,53,129,135,153,161,173,180,184,197,234,254],"nonclinical":[8],"studies":[9],"implicate":[10],"tumour":[11],"necrosis":[12],"factor":[13],"\u03b1-like":[14],"ligand":[15],"1A":[16],"(TL1A)":[17],"as":[18],"a":[19,28],"novel":[20],"target":[21],"in":[22,57,178,217,250],"inflammatory":[23,256],"bowel":[24],"disease":[25],"(IBD).":[26],"PF-06480605,":[27],"fully":[29],"human":[30],"immunoglobulin":[31],"G1":[32],"monoclonal":[33],"antibody,":[34],"targets":[35],"TL1A.":[36],"This":[37],"first-in-human,":[38],"Phase":[39],"1,":[40],"dose-escalation":[41],"study":[42,247],"assessed":[43,141],"safety,":[44,203],"tolerability,":[45,125],"pharmacokinetics,":[46,126,204],"pharmacodynamics":[47,206],"immunogenicity":[49,127],"of":[50,236,248],"intravenous":[51],"(IV)":[52],"subcutaneous":[54],"(SC)":[55],"PF-06480605":[56,71,95,146,191,224,229,249],"healthy":[58],"subjects":[59,63],"(NCT01989143).":[60],"METHODS:":[61],"Ninety-two":[62],"were":[64,140,166,171],"randomized":[65],"to":[66,149,156],"single":[67],"ascending":[68,92],"doses":[69,93],"(SAD),":[70],"1":[72],"mg,":[73,75,77,79,81,83,105,109],"3":[74,96,102,106,111],"10":[76],"30":[78,104],"100":[80,108],"300":[82,113,157],"600":[84],"mg":[85,88,99,114,151,158,163],"or":[86,90,101,110,122,187,205],"800":[87,150],"IV,":[89,100],"multiple":[91],"(MAD),":[94],"\u00d7":[97,103,107,112],"500":[98,162],"SC":[115,160],"every":[116],"2":[117],"weeks":[118],"for":[119,223],"three":[120],"doses,":[121],"placebo.":[123],"Safety,":[124],"profiles":[128],"total":[130,219],"TL1A,":[131],"anti-drug":[132],"antibody":[133,137],"(ADA)":[134],"neutralizing":[136],"(NAb)":[138],"levels":[139,199],"at":[142,207],"pre-determined":[143],"times.":[144],"RESULTS:":[145],"SAD":[147,179],"up":[148,155],"IV":[152,165],"MAD":[154,181],"\u00d73":[159,164],"well":[167,232],"tolerated.":[168],"Overall,":[169],"there":[170],"45":[172],"44":[174],"treatment-emergent":[175],"adverse":[176,189],"events":[177],"cohorts,":[182],"respectively,":[183],"no":[185],"deaths":[186],"serious":[188],"events.":[190],"exposure":[192],"generally":[193,231],"increased":[194],"dose-dependently.":[195],"ADA":[196],"NAb":[198],"did":[200],"not":[201],"impact":[202],"higher":[208],"doses.":[209],"Target":[210],"engagement":[211],"was":[212,230,239],"demonstrated":[213],"through":[214],"dose-dependent":[215],"differences":[216],"serum":[218],"soluble":[220,237],"TL1A":[221,238],"concentrations":[222],"vs":[225],"placebo":[226],"cohorts.":[227],"CONCLUSIONS:":[228],"tolerated,":[233],"binding":[235],"maintained":[240],"throughout":[241],"the":[242],"dose":[243],"interval,":[244],"supporting":[245],"further":[246],"patients":[251],"with":[252],"IBD":[253],"other":[255],"conditions.":[257]},"counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":10},{"year":2024,"cited_by_count":5},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2019-12-05T00:00:00"}